ME1 and pancreatic adenocarcinoma: In cancer, particularly in KRAS-dependent pancreatic adenocarcinoma, the Glutamate Oxaloacetate Transaminase 1 (GOT1)-MDH1-ME1 axis is reprogrammed to enhance NADPH production; silencing GOT1 or suppressing ME1 leads to intracellular ROS accumulation, redox imbalance, and loss of proliferation (66).